Global Fibromyalgia Drugs Market Revenue Analysis and Forecasts Report 2019

The analysts forecast the global fibromyalgia drugs market to grow at a CAGR of 0.79% over the period 2014-2019.

According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, fibromyalgia is a syndrome with an unknown cause and chronic pain and muscle tenderness as the major symptoms. Unlike arthritis, it does not cause joint, muscle or other tissue inflammation. However, fibromyalgia is known to cause impairment of joints, soft tissues, and causes significant pain and fatigue. Fibromyalgia affects women more than men. In the US, the condition affects more than 5 million people aged 18 years and above, of which 80-90% are women. There is no particular diagnostic test for detecting fibromyalgia, and physicians undertake differential diagnosis to check the presence of the syndrome. Currently in the US, only three drugs are approved to treat fibromyalgia. Off-label treatment is a popular option to treat fibromyalgia using analgesics, antidepressants, sedatives, neuroleptics, and muscle relaxants.

Covered in this Report

This report covers the present scenario and the growth prospects of the global fibromyalgia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of fibromyalgia.

Based on the chemical class of the drugs used to treat fibromyalgia, the market is segmented as follows:
Serotonin norepinephrine reuptake inhibitors
GABA analogs

The report, the Global Fibromyalgia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.

This report includes a discussion of the market in the following three regions:
Americas: The major countries here are the US, Canada, Mexico, and Brazil
EMEA: The major countries here are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
APAC: The major countries here are Japan, China, Australia, Singapore, South Korea, and India.

APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Purchase a copy of the report at .

Key Regions


Key Vendors

Eli Lilly

Other Prominent Vendors

Daiichi Sankyo
Innovative Med Concepts
Meiji Seika
Merck Sharp and Dohme
Switch Biotech
Zynerba Pharmaceuticals

Key Market Driver

Unmet Medical Needs

Key Market Challenge

Adverse Events

Key Market Trend

Expected Entry of “”Me-too”" Drugs

Key Questions Answered in this Report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

For more Information on the report, inquire at .

About US: is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.